Kexing Biopharm (688136.SH) terminates clinical trial of recombinant human interferon 2b nasal spray.

Kexing Biopharm (688136.SH) announced that the company's development of interferon 2b nasal spray is in the clinical research stage. Recently, after careful consideration of the drug's future development risks, the company has decided to terminate the clinical trials of this project.